Wordt geladen...
Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
Rituximab has been established as an effective and safe therapy for cutaneous B-cell lymphoma (CBCL). Different survival pathways, that is the Raf/MEK/Erk- or the p38MAPK cascade, have been suggested as downstream mediators of rituximab and may be involved in treatment failure. Biopsies from four pa...
Bewaard in:
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2007
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2359948/ https://ncbi.nlm.nih.gov/pubmed/17473827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603762 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|